Thank you...After two months of negotiations between Denner and Olsen, the gloves have finally come off... IMO it would be serious mistake for shareholders to let Denner fail in his mission to increase the value of Amarin, which has been inherent in its product, Vascepa, but has gone unrecognized. Despite the valiant efforts of KM, the time has come for Denner try his expert hand.